Skip to main content
Premium Trial:

Request an Annual Quote

Todos Medical Inks Preferred Supplier Deal With Pangea for COVID-19 Tests

NEW YORK – Todos Medical said on Wednesday it is partnering with Pangea to be its preferred supplier of COVID-19 testing products.

As part of the deal, Todos will be the preferred supplier of such products for Pangea's offerings for contract tracing and so-called COVID-19 passport services in Israel and parts of Africa. Todos said it will also integrate and tailor Pangea's technology into its service offerings in the US, Canada, and Mexico to create "COVID bubbles" for employers, schools, sports leagues, and other clients.

Financial and other terms of the deal were not disclosed.

Israel-based Pangea is a supplier of digital identity, security, and ePayment solutions.

Earlier this week, Todos, also headquartered in Israel, announced a sales agreement with an unnamed laboratory in Wisconsin for a $23.8 million contract. The lab, it said, has an agreement with the state of Wisconsin to supply COVID-19 PCR tests. 

Todos will supply the lab with testing equipment and supplies, including automated extraction machines, liquid handlers, and PCR instruments.

The initial contract is for eight months, and Todos has been granted a priority right to supply the lab with up to 100,000 COVID PCR tests per day if the lab sees significant additional testing demand.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.